ATE364717T1 - Diagnose durch bestimmung von polymorphismen in der promoterregion des tgf-beta 1 gens - Google Patents

Diagnose durch bestimmung von polymorphismen in der promoterregion des tgf-beta 1 gens

Info

Publication number
ATE364717T1
ATE364717T1 AT97915646T AT97915646T ATE364717T1 AT E364717 T1 ATE364717 T1 AT E364717T1 AT 97915646 T AT97915646 T AT 97915646T AT 97915646 T AT97915646 T AT 97915646T AT E364717 T1 ATE364717 T1 AT E364717T1
Authority
AT
Austria
Prior art keywords
tgf
beta
diagnosis
gene
promoter region
Prior art date
Application number
AT97915646T
Other languages
English (en)
Inventor
David John Grainger
Timothy David Spector
Kirsten Heathcote
Original Assignee
Sequenom Gemini Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9600957.6A external-priority patent/GB9600957D0/en
Priority claimed from GBGB9617674.8A external-priority patent/GB9617674D0/en
Application filed by Sequenom Gemini Ltd filed Critical Sequenom Gemini Ltd
Application granted granted Critical
Publication of ATE364717T1 publication Critical patent/ATE364717T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • External Artificial Organs (AREA)
AT97915646T 1996-01-17 1997-01-17 Diagnose durch bestimmung von polymorphismen in der promoterregion des tgf-beta 1 gens ATE364717T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9600957.6A GB9600957D0 (en) 1996-01-17 1996-01-17 Diagnostic method and apparatus
GBGB9617674.8A GB9617674D0 (en) 1996-08-23 1996-08-23 Diagnostic method and apparatus

Publications (1)

Publication Number Publication Date
ATE364717T1 true ATE364717T1 (de) 2007-07-15

Family

ID=26308478

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97915646T ATE364717T1 (de) 1996-01-17 1997-01-17 Diagnose durch bestimmung von polymorphismen in der promoterregion des tgf-beta 1 gens

Country Status (9)

Country Link
US (1) US5998137A (de)
EP (1) EP0889972B1 (de)
JP (1) JP2000504226A (de)
AT (1) ATE364717T1 (de)
AU (1) AU723751B2 (de)
CA (1) CA2243191A1 (de)
DE (1) DE69737812T2 (de)
NZ (1) NZ331041A (de)
WO (1) WO1997028280A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
GB9822682D0 (en) * 1998-10-16 1998-12-09 Gemini Research Limited Diagnostic method and apparatus based on polymorphism in a TGF-B-Gene
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040209254A1 (en) * 2000-07-25 2004-10-21 Henderson Lee A. Diagnostic polymorphisms for the tgf-beta1 promoter
GB0111277D0 (en) * 2001-05-09 2001-06-27 Univ Sheffield Gentle marker
GB2381526A (en) * 2001-11-03 2003-05-07 Sequenom Inc Detection of predisposition to osteoporosis
KR20040008815A (ko) * 2002-07-19 2004-01-31 한미약품 주식회사 혈장 내 전환성장인자-베타 1의 정량 방법
WO2008049953A1 (es) 2006-10-23 2008-05-02 Neocodex, S.L. Método de pronóstico y/o diagnóstico in vitro de hipersensibilidad a estrógenos o a sustancias con actividad estrogénica
HU227658B1 (en) * 2007-04-27 2011-10-28 Univ Szegedi Process for diagnosting of susceptibility to posttraumatic respiratory scaring
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
ATE167525T1 (de) * 1991-07-01 1998-07-15 Blood Center Of Southeastern W Pen-polymorphismus von menschlichem plättchenmembran-glykoprotein-iiia und diagnostische und therapeutische anwendung davon
DE69333659T2 (de) * 1992-07-31 2005-11-17 Garvan Institute Of Medical Research, Darlinghurst Einschätzung von in trans-agierenden faktoren der allelen variation
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
AU1214995A (en) * 1993-11-30 1995-06-19 California Pacific Medical Center Research Institute Cdna probe for breast cancer diagnosis and treatment
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis

Also Published As

Publication number Publication date
EP0889972B1 (de) 2007-06-13
JP2000504226A (ja) 2000-04-11
WO1997028280A1 (en) 1997-08-07
EP0889972A1 (de) 1999-01-13
AU2304697A (en) 1997-08-22
DE69737812D1 (de) 2007-07-26
NZ331041A (en) 2001-06-29
AU723751B2 (en) 2000-09-07
CA2243191A1 (en) 1997-08-07
US5998137A (en) 1999-12-07
DE69737812T2 (de) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE364717T1 (de) Diagnose durch bestimmung von polymorphismen in der promoterregion des tgf-beta 1 gens
DE3574994D1 (de) Sandwichhybridisierungsverfahren zum nachweis von nukleotidsequenzen.
FI871310A0 (fi) Foerfarande foer snabbloesning av polymergeler i vatten.
DE69013630D1 (de) Verfahren zum Verbinden von korrosionsbeständigen Werkstoffen durch Diffusion.
DE69523586D1 (de) Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
IT8822157A0 (it) Installazione ausiliaria per la diagnostica di patologie cardiovascolari e polmonari
PT948604E (pt) Produtos e metodos relacionados com pyk2
ATE81750T1 (de) Verfahren zum einlegen oder einpoekeln von fleisch.
NO872773D0 (no) Korrosjons- og slitasjeresistent staal.
IT9067530A0 (it) Procedimento di ammollo enzimatico per pelli e pellami.
IT1149679B (it) Processo per affinazione di acciai ad elevato tenore di cromo
CA2251744A1 (en) Methods for identifying predisposition to osteoarthritis by a vitamin d receptor genotype
DE69739183D1 (de) Bestimmung des kollagen genotyps
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
DE69018500D1 (de) Verfahren zur Schmelzreduktion von Nickelerzen.
NO882593D0 (no) Forbedret nykleinsyrehybridiseringsteknikk og kit til dette.
IT1139353B (it) Procedimento e dispositivo per la lavorazione,preferibilmente per la fresatura o la levigatura di bordi e raggi su pezzi in un'unica operazione
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
DE69734890D1 (de) Rdgb-proteine
DE3580820D1 (de) Cursor fuer einen elektromagnetischen digitizer und verfahren zum herstellen desselben.
FI913417A0 (fi) Anordning vid vattensaeng.
DE69023710D1 (de) Verfahren zur bestimmung von enzymatischer wirksamkeit.
FR2668162B1 (fr) Fragments d'adn, procede et coffret de diagnostic pour la detection des porteurs de la mutation delta-f-508 responsable de la mucoviscidose.
DE3764814D1 (de) Flaechige, korrosionsbestaendige apparateteile.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889972

Country of ref document: EP

REN Ceased due to non-payment of the annual fee